Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)
2017-003724-79Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of canakinumab in alcoholic hepatitis (AH), sponsored by Imperial College London. Primary endpoint: Histological improvement of alcoholic hepatitis at Day 28. Status: unknown.
02
Drugs
canakinumab
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on 2017-003724-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003724-79.